ANSWER: C

Rationale:

Amphetamine's reverse transport mechanism is mechanistically distinct from reuptake inhibition and is the key pharmacological feature that explains its independence from neuronal firing. Amphetamine (pKa approximately 9.9, moderately lipophilic) enters the presynaptic terminal by two routes: passive diffusion across the cell membrane and active carrier-mediated uptake via NET (the same transporter that normally removes NE from the cleft). Once intraneuronal, amphetamine enters synaptic vesicles via VMAT2 (competing with catecholamines for the vesicular proton antiporter), disrupts the acidic vesicular pH gradient that normally drives catecholamine packaging, and causes NE to leak down its concentration gradient from the vesicular lumen into the cytoplasm. As cytoplasmic NE concentration rises, the NET transporter is driven to operate in reverse (efflux) mode -- transporting NE from the cytoplasm outward into the synaptic cleft without requiring vesicular exocytosis or calcium-triggered fusion; this is carrier-mediated efflux, entirely distinct from exocytosis. The efflux is action-potential-independent because it does not require the calcium influx that triggers vesicular release; tetrodotoxin (which blocks voltage-gated Na+ channels and prevents action potentials) does not prevent amphetamine-induced NE release. Amphetamine additionally inhibits MAO-A and MAO-B (increasing the cytoplasmic NE pool available for efflux) and competitively inhibits NET for the inward direction (reducing NE reuptake). Reuptake inhibition (cocaine, methylphenidate) by contrast does not enter the terminal, does not reverse transport direction, and absolutely requires ongoing neuronal activity and vesicular NE release for its effects -- these agents amplify the signal from firing neurons but cannot create a signal from silent neurons. This mechanistic distinction has important pharmacological consequences: amphetamine depletes vesicular NE stores with chronic use (producing tolerance from catecholamine depletion), while reuptake inhibitors do not deplete stores.

• Option A: Option A is incorrect: amphetamine and cocaine do not act by identical mechanisms; cocaine binds to the extracellular face of NET/DAT/SERT and blocks reuptake (a reuptake inhibitor); amphetamine enters the nerve terminal via NET/DAT and acts intracellularly to promote reverse transport (efflux) of NE and dopamine — a fundamentally different mechanism that depletes vesicular stores over time, whereas cocaine does not; their clinical profiles differ accordingly (amphetamine produces tolerance from store depletion; cocaine does not).
• Option B: Option B correctly identifies TAAR1 as involved in amphetamine's intraneuronal signaling but overstates its role as the exclusive reverse transport mechanism; the TAAR1-PKC pathway is a modulatory amplifier, not the primary transport driver.
• Option D: Option D is incorrect: amphetamine does not produce its sympathomimetic effects exclusively through MAO inhibition; while amphetamine is a substrate for MAO and does have some MAO-inhibiting properties at high concentrations, its primary mechanism is reverse transport via NET and DAT — promoting NE and dopamine efflux from nerve terminals independently of MAO inhibition; MAO inhibition is the mechanism of phenelzine and tranylcypromine, not amphetamine.
• Option E: Option E is incorrect: amphetamine does not act through a purely physical "lock and key tight binding" mechanism that physically ejects NE; the reverse transport mechanism requires amphetamine to enter the nerve terminal via the transporter and then disrupt the electrochemical gradient driving NE into vesicles (via VMAT2 displacement), and activate signaling pathways (TAAR1) that phosphorylate the transporter to facilitate outward NE efflux; this is an active pharmacological process requiring specific molecular interactions, not simple competitive displacement.

ANSWER: A

Rationale:

Cocaine's dual pharmacology is one of the most elegant examples in clinical pharmacology of a single molecule having two completely independent mechanisms with complementary clinical utility. Local anesthetic mechanism: cocaine blocks voltage-gated sodium channels (specifically Nav1 isoforms expressed in peripheral sensory and motor nerve fibers) by binding within the channel pore from the intracellular face (after crossing the axonal membrane in its uncharged lipophilic form); this blocks Na+ influx during the rising phase of the action potential, preventing membrane depolarization and propagation of the action potential; the result is dose-dependent reduction and abolition of nerve conduction, producing sensory block (anesthesia), motor block, and autonomic block in the anesthetized territory; this Na+ channel mechanism is shared by all clinical local anesthetics (lidocaine, bupivacaine, ropivacaine, articaine) and has absolutely nothing to do with monoamine transporters. Sympathomimetic mechanism: cocaine blocks NET, DAT, and SERT with relatively equal affinity by binding within the transporter substrate recognition site, occluding the inward transport of monoamines from the synapse; the accumulated NE at alpha-1 receptors on submucosal arterioles and venous sinusoids of the nasal mucosa produces intense vasoconstriction, reducing mucosal engorgement, nasal blood flow, and bleeding. Clinical uniqueness: cocaine is the only drug combining topical Na+ channel local anesthesia with NET-mediated vasoconstriction applicable to mucosal surfaces; epinephrine added to lidocaine achieves a superficially similar combination but through different mechanisms and is not equivalent topically (epinephrine is not absorbed well through intact mucosa at typical concentrations; cocaine's NET blockade produces vasoconstriction through accumulated endogenous NE, which is more reliably effective on nasal mucosal vasculature); cocaine topical solution (4-10%) for ENT procedures is the only legitimate contemporary medical use of cocaine.

• Option B: Option B is incorrect -- NET and Nav1 do not share structural pore homology and their blocking is mechanistically independent.
• Option C: Option C is incorrect: cocaine's local anesthetic effect is not produced by beta-2 receptor activation on sensory neurons; it is produced by sodium channel (Nav1) blockade — the same mechanism as lidocaine; beta-2 receptors are absent on sensory neurons in significant numbers, and beta-2-mediated cAMP-PKA effects would reduce sensory neuron excitability but through a different pathway than the fast sodium channel block that defines local anesthesia; cocaine's anesthetic mechanism is Na+ channel blockade, unrelated to adrenergic receptors.
• Option D: Option D is incorrect: cocaine is not the only drug with dual local anesthetic and sympathomimetic properties as unique features; the key point is not that the combination is unique but that cocaine's ability to provide both local anesthesia AND vasoconstriction in mucous membranes via a single molecule is uniquely useful for ENT procedures — cocaine is the only topical anesthetic that also produces the hemostatic effect needed for nasal surgery in the same molecule; other combinations (epinephrine added to lidocaine) achieve both effects but through separate drugs.
• Option E: Option E is incorrect: cocaine's local anesthetic mechanism does not require systemic absorption to reach Nav1 channels in dorsal root ganglia; topical cocaine applied to nasal mucosa produces local anesthesia by directly blocking Nav1 channels in the mucosal sensory nerve endings without systemic absorption; this is the fundamental principle of topical/local anesthesia — the drug acts at the site of application on local nerve endings, not via systemic circulation to ganglia.

ANSWER: E

Rationale:

The methylphenidate-versus-amphetamine mechanistic distinction is one of the most clinically important and frequently tested concepts in stimulant pharmacology. Methylphenidate mechanism: methylphenidate is a piperidine derivative structurally unrelated to the phenylethylamine backbone of amphetamines; it binds to the substrate recognition site of NET and DAT from the extracellular face, occluding the transporter and preventing inward transport of NE and dopamine from the synapse; methylphenidate does not enter the presynaptic terminal in pharmacologically significant amounts and does not reverse transporter direction; critically, methylphenidate's mechanism depends entirely on ongoing neuronal firing -- the neuron must fire, release NE/dopamine by calcium-triggered vesicular exocytosis, and then the synaptically released NE/dopamine accumulates because reuptake is blocked; if the neuron is silent, there is nothing in the synapse to accumulate; methylphenidate therefore selectively amplifies signals from neurons that are already active. Amphetamine mechanism: amphetamine enters the terminal, disrupts vesicular pH, causes NE/dopamine efflux by reverse transport, and releases NE/dopamine independent of neuronal firing -- it creates a signal even from silent neurons. Clinical implications: methylphenidate's activity-dependent mechanism may contribute to its somewhat more physiological cognitive effect profile compared to amphetamines; both produce equivalent symptomatic improvement in ADHD at therapeutic doses in most patients; abuse potential of methylphenidate (when taken as prescribed orally and not manipulated) is considered somewhat lower than amphetamines because the reuptake inhibition mechanism rises and falls more gradually with oral pharmacokinetics than the sharp catecholamine efflux of amphetamine.

• Option A: Option A is incorrect: methylphenidate and amphetamine do not have identical mechanisms; amphetamine promotes reverse transport (NE and dopamine efflux) through NET/DAT, depleting vesicular stores with chronic use; methylphenidate is a reuptake inhibitor (blocks NET and DAT without entering the terminal) that does not promote reverse transport or vesicular depletion; these mechanistic differences result in different tolerance profiles and different ADHD efficacy in treatment-resistant patients.
• Option B: Option B is incorrect: methylphenidate does not act by directly activating dopamine D1 receptors in the PFC; it is a NET and DAT reuptake inhibitor; D1 receptor activation is the downstream consequence of increased synaptic dopamine from DAT blockade in PFC neurons, not a direct drug-receptor interaction; direct D1 agonism in the PFC would bypass the transporter mechanism and represent a completely different drug class.
• Option C: Option C is incorrect: methylphenidate is not a selective alpha-2A agonist; it is a NET/DAT reuptake inhibitor; alpha-2A agonism in the PFC is the mechanism of guanfacine (which closes HCN channels and strengthens PFC network connectivity) — a fundamentally different mechanism from methylphenidate's transporter inhibition; conflating these two distinct ADHD mechanisms misrepresents both pharmacological classes.
• Option D: Option D is partially correct in identifying methylphenidate as a NET/DAT reuptake inhibitor that is structurally distinct from amphetamines; however, Option E is the correct answer because it provides the most mechanistically complete account — specifically explaining that methylphenidate's NE effects in the PFC (via NET blockade) contribute importantly to its ADHD efficacy, and that its slower onset/offset profile with oral pharmacokinetics reduces the sharp catecholamine efflux that produces amphetamine's abuse potential.

ANSWER: B

Rationale:

The physiological protection against dietary tyramine toxicity is one of the most clinically important pharmacological concepts related to MAOIs, as its abolition explains the cheese effect. Under normal conditions: tyramine (a monoamine formed by the decarboxylation of tyrosine during bacterial fermentation of foods) is present in high concentrations in aged cheeses, cured meats, fermented beverages, pickled fish, soy sauce, and miso; it is readily absorbed from the small intestine; however, the intestinal wall epithelium expresses high levels of MAO-A (the isoform responsible for oxidative deamination of dietary monoamines including tyramine, serotonin, and to some extent dopamine); MAO-A in enterocytes oxidatively deaminates absorbed tyramine to 4-hydroxyphenylacetaldehyde and then 4-hydroxyphenylacetic acid (inactive) before it reaches the portal vein; any tyramine that survives intestinal MAO-A encounters hepatic MAO-A in the hepatocytes during first-pass transit; the combination of intestinal wall plus hepatic first-pass MAO-A effectively eliminates virtually all ingested tyramine before it enters the systemic circulation; this system handles very large tyramine loads safely -- eating a large portion of aged cheese does not raise blood pressure measurably in non-MAOI-treated individuals. MAOI abolition of this protection: phenelzine, tranylcypromine, isocarboxazid, and other irreversible non-selective MAOIs covalently and irreversibly inhibit MAO-A at both the intestinal wall and hepatic level; dietary tyramine then passes through these two protective sites without degradation; the amount reaching the systemic circulation can be 50-100 times greater than normal; systemic tyramine is taken up by sympathetic nerve terminals via NET and promotes massive NE efflux, producing the hypertensive crisis. The threshold dose of dietary tyramine needed to produce a pressor response falls from approximately 400-500 mg (safe, cannot be achieved by normal eating) in healthy subjects to as little as 10-20 mg in MAOI-treated patients -- an amount easily exceeded by a portion of aged cheddar or blue cheese.

• Option A: Option A is incorrect: tyramine is not too large or too polar to be absorbed from the GI tract; tyramine is a small aromatic amine (molecular weight 137 daltons) with moderate lipophilicity that is readily absorbed across intestinal epithelium; the reason tyramine is normally harmless is not a barrier to absorption but rather efficient first-pass MAO-A degradation in the intestinal wall and liver that prevents absorbed tyramine from reaching the systemic circulation.
• Option C: Option C is incorrect: tyramine is not recognized by the gut immune system (GALT) and degraded by macrophages; this is a fabricated mechanism; the physiological protection against dietary tyramine is enzymatic (MAO-A in the intestinal wall and hepatocytes performing first-pass oxidative deamination), not immunological.
• Option D: Option D is incorrect: tyramine is pharmacologically active at adrenergic receptors — specifically, it is an indirect sympathomimetic that enters nerve terminals via NET and promotes NE release; in healthy subjects with intact MAO activity, absorbed tyramine is efficiently cleared before reaching nerve terminals in significant amounts; in MAOI-treated patients, the residual tyramine that escapes gut MAO enters the systemic circulation, reaches sympathetic terminals, and triggers massive NE release.

ANSWER: D

Rationale:

The tyramine pressor response sequence in MAOI-treated patients involves a cascade of events at multiple anatomical levels, each amplified by the loss of MAO-mediated inactivation. Step 1 -- bypass of first-pass MAO-A protection: normally intestinal wall and hepatic MAO-A degrades dietary tyramine before it reaches the systemic circulation; in MAOI-treated patients this protection is abolished; tyramine reaches systemic arterial blood intact. Step 2 -- NET-mediated neuronal uptake: tyramine is structurally similar to NE (a para-hydroxyphenylethylamine) and is a substrate for NET; it enters peripheral sympathetic terminals via NET. Step 3 -- vesicular displacement and reverse efflux: intraneuronal tyramine competes with NE for VMAT2 uptake into synaptic vesicles and disrupts the vesicular proton gradient, causing NE to leak from vesicles into the cytoplasm; rising cytoplasmic NE drives NET into reverse efflux mode, transporting NE into the synaptic cleft. Step 4 -- loss of inactivation: normally released or displaced NE re-entering the cytoplasm is rapidly degraded by MAO-A; the MAOI has abolished this degradation; cytoplasmic NE accumulates and efflux continues; simultaneously, any NE in the synapse that could be re-taken up and MAO-degraded is also protected from inactivation. Step 5 -- receptor activation: massive synaptic NE activates alpha-1 receptors (Gq-IP3-Ca2+-MLCK: vasoconstriction, severe hypertension) and beta-1 receptors (tachycardia, increased contractility); the clinical result is acute severe hypertension with pounding headache, diaphoresis, pallor, and palpitations -- the cheese effect. Acute management rationale: phentolamine IV directly blocks the alpha-1 receptors being activated by the NE flood, reducing SVR and BP; it is the most targeted pharmacological reversal; sodium nitroprusside provides additional vasodilation via NO-cGMP pathway downstream of the alpha receptor; non-selective beta-blockers are absolutely contraindicated -- removing beta-2 vasodilation while alpha-1 vasoconstriction is maximal worsens hypertension dramatically. Options B and D describe the same correct mechanism; D is the most complete, including both vesicular displacement and the reverse efflux step explicitly.

• Option A: Option A is incorrect: tyramine itself does not directly activate alpha-1 adrenergic receptors with moderate affinity; tyramine has very low direct receptor affinity and acts predominantly as an indirect sympathomimetic by releasing endogenous NE from sympathetic terminals via NET-mediated reverse transport; it is the released NE that activates alpha-1 receptors and produces vasoconstriction — tyramine itself is not the direct receptor agonist.
• Option B: Option B partially correctly identifies the mechanism (tyramine enters via NET, disrupts vesicular pH, promotes NE efflux) but omits the critical role of MAO-A inhibition in allowing tyramine to reach sympathetic terminals in the first place; in MAOI-treated patients, tyramine escapes gut wall first-pass MAO degradation, enters systemic circulation, reaches sympathetic terminals via NET, and then promotes NE efflux; without MAOI, systemic tyramine concentrations after a cheese meal are negligible.
• Option C: Option C is incorrect: tyramine does not cause hypertensive crisis through PNMT inhibition causing adrenal chromaffin cells to release epinephrine instead of norepinephrine; this mechanism is pharmacologically implausible — PNMT inhibition would reduce epinephrine synthesis (converting less dopamine to NE-to-Epi), not trigger catecholamine release; the adrenal chromaffin mechanism is not the basis for tyramine-induced hypertensive crisis in MAOI-treated patients.
• Option E: Option E is incorrect: tyramine does not trigger hypertensive crisis through a serotonergic mechanism; tyramine is not converted intraneuronally to dopamine by AADC to trigger serotonin release; tyramine is an indirect sympathomimetic acting on NE-releasing neurons via NET; while tyramine does have some structural similarity to monoamines, it is not a serotonin precursor and does not produce serotonin syndrome — the crisis is adrenergic (NE-mediated vasoconstriction), not serotonergic.

ANSWER: A

Rationale:

VMAT2 is a critical presynaptic storage mechanism whose irreversible inhibition by reserpine provides a teaching model for understanding the consequences of monoamine vesicular storage disruption. VMAT2 function: expressed on the membrane of synaptic vesicles in monoaminergic neurons throughout the central and peripheral nervous system; uses the vesicular electrochemical proton gradient (generated by a V-type H+-ATPase that pumps H+ into the vesicle lumen, making it acidic and electropositive relative to the cytoplasm) to drive antiport: one monoamine molecule enters the vesicle for every two H+ ions that exit; VMAT2 handles all monoamines including NE, dopamine, epinephrine, serotonin, and histamine; it is distinct from VMAT1 (expressed in adrenal chromaffin cells and peripheral neuroendocrine cells) by its higher affinity for dopamine and lower affinity for epinephrine. Reserpine mechanism: reserpine is a lipophilic alkaloid that partitions into vesicular membranes and binds VMAT2 at its cytoplasmic face; the binding involves hydrophobic interactions and is essentially irreversible under physiological conditions (koff is vanishingly slow); VMAT2 inactivation prevents catecholamine packaging into vesicles; cytoplasmic NE, dopamine, and serotonin are instead degraded by MAO-A and MAO-B; vesicular monoamine stores progressively deplete over days to weeks; sympathetic nerve stimulation can no longer trigger meaningful NE release (empty vesicles cannot undergo productive exocytosis). Irreversibility and duration: because reserpine inactivates VMAT2 permanently, recovery requires synthesis of new VMAT2 protein from the SLC18A2 (vesicular monoamine transporter 2 gene) gene; protein synthesis and vesicular membrane assembly and transport to nerve terminals takes days to weeks; reserpine effects therefore persist weeks after the last dose despite reserpine itself being cleared from plasma within hours to days; this is analogous to the recovery from aspirin's irreversible COX inhibition requiring new platelet synthesis. Systemic monoamine depletion: reserpine depletes NE (sympathetic neurons, adrenal medulla), dopamine (nigrostriatal and mesolimbic pathways), and serotonin (raphe nuclei, gut) -- explaining its adverse effects of depression (serotonin and NE depletion), Parkinson-like extrapyramidal symptoms (nigrostriatal dopamine depletion), and sedation.

• Option B: Option B is incorrect: VMAT2 does not transport NE from vesicles into the cytoplasm for release; VMAT2 functions in the opposite direction — it transports cytoplasmic NE (and other monoamines) into synaptic vesicles for storage and eventual exocytotic release; reserpine inhibits this inward transport from cytoplasm to vesicle, causing NE to remain in the cytoplasm where it is degraded by MAO, resulting in progressive vesicular NE depletion.
• Option C: Option C is incorrect: VMAT2 is located on the vesicular membrane (not the presynaptic terminal membrane), and it transports monoamines from the cytoplasm into vesicles (not from the synapse into the cytoplasm); NET (the norepinephrine transporter) is the membrane protein responsible for reuptake from the synapse into the cytoplasm; VMAT2 and NET are two distinct transporters with opposite topological orientations and functions.
• Option D: Option D is incorrect: VMAT2 transports all three catecholamines (dopamine, NE, epinephrine) as well as serotonin and histamine into vesicles; it is not selective for dopamine only; reserpine inhibits VMAT2 throughout the body, depleting monoamine stores in peripheral sympathetic neurons (NE), adrenal chromaffin cells (Epi + NE), dopaminergic neurons (dopamine), and serotonergic neurons (serotonin) — which is why its adverse effects include depression (serotonin + NE depletion) and Parkinson-like symptoms (dopamine depletion) simultaneously.

ANSWER: C

Rationale:

Guanethidine's mechanism and its drug interaction with NET blockers illustrates the principle that a drug's mechanism of action determines its vulnerability to pharmacokinetic and pharmacodynamic interactions. Guanethidine mechanism: guanethidine is a highly polar, positively charged guanidinium compound at physiological pH; it cannot cross lipid membranes by passive diffusion and requires active carrier-mediated transport for cellular entry; NET (the norepinephrine transporter on the presynaptic sympathetic terminal) is the exclusive entry mechanism for guanethidine into sympathetic neurons; once inside the terminal, guanethidine accumulates in synaptic vesicles (concentrated by the VMAT2 proton gradient just as NE is, because guanethidine is a protonatable amine); intravesicular guanethidine then: (1) inhibits the calcium-triggered exocytosis mechanism that couples action potential arrival to vesicular fusion and NE release; (2) displaces NE from vesicles (initially causing a transient NE release and brief BP rise); (3) over days to weeks, progressively depletes vesicular NE through ongoing displacement without adequate replenishment; the combined effect is sympatholysis: reduced NE release per action potential, and eventually near-abolition of functional NE stores. Comparison to reserpine: reserpine directly blocks VMAT2 on the vesicular membrane (inhibiting catecholamine packaging); its sympatholytic effect does not require NET-mediated terminal entry and is therefore unaffected by NET blockade; guanethidine requires NET for terminal entry and is completely dependent on functional NET. The NET-blocker interaction: TCAs, cocaine, amphetamines, and methylphenidate all block NET; by blocking NET, these drugs prevent guanethidine from entering the sympathetic terminal entirely; guanethidine remains in the extracellular space and cannot access its site of action; the antihypertensive effect is completely reversed; this interaction was of major historical clinical importance when guanethidine was used as an antihypertensive -- patients who also needed antidepressant therapy could not receive TCAs without losing blood pressure control.

• Option A: Option A is incorrect: guanethidine does not act by irreversible VMAT2 inhibition like reserpine; guanethidine enters sympathetic nerve terminals via NET and accumulates there, displacing NE from storage vesicles and also blocking the NE release mechanism (preventing vesicle-membrane fusion during action potentials); this is a NET-accumulation and release-blocking mechanism, distinct from VMAT2 inhibition; the selectivity noted (only peripheral sympathetic neurons, sparing CNS) reflects guanethidine's inability to cross the blood-brain barrier, not selective VMAT2 targeting.
• Option B: Option B correctly identifies the mechanism and interaction; it is the most pharmacologically accurate answer.
• Option D: Option D is incorrect: guanethidine does not inhibit dopamine beta-hydroxylase (DbH), the enzyme that converts dopamine to NE; its mechanism is accumulation in the nerve terminal via NET-mediated uptake and then blockade of NE release from vesicles during sympathetic stimulation (local anesthetic-like membrane stabilization preventing exocytosis), combined with gradual NE depletion from vesicular displacement; DbH inhibition is not part of guanethidine's pharmacology.

ANSWER: E

Rationale:

Ephedrine's mixed mechanism and structural basis for oral bioavailability are pharmacological principles that bridge the catecholamine and non-catecholamine classes. Ephedrine mechanism -- direct component: ephedrine directly activates alpha-1, beta-1, and beta-2 adrenergic receptors with modest potency; it has sufficient structural similarity to NE (phenylethylamine backbone with para-hydroxyl) to bind adrenergic receptors without requiring NE release; the direct component is responsible for a portion of its cardiovascular effects (vasoconstriction, cardiac stimulation, bronchodilation) that persist even in catecholamine-depleted states. Ephedrine mechanism -- indirect component: ephedrine also enters presynaptic sympathetic terminals via NET and promotes carrier-mediated NE reverse efflux (same general mechanism as amphetamine, though less potent); the indirect component accounts for a significant portion of ephedrine's pressor effect; because it partially depends on NE store availability, ephedrine shows tachyphylaxis with repeated doses (stores deplete between doses) and its effects are attenuated (though not eliminated) after reserpine pretreatment. Oral bioavailability structural basis: (1) No catechol ring: ephedrine has a single para-hydroxyl on the phenyl ring (not the 3,4-dihydroxyl catechol pattern); without the catechol ring, COMT cannot metabolize ephedrine (COMT requires the 3-hydroxyl for O-methylation); (2) Alpha-methyl group: ephedrine has a methyl group on the alpha-carbon of the ethylamine side chain; MAO oxidizes monoamines at the alpha-carbon; the alpha-methyl group sterically impedes MAO's access to the amine and dramatically reduces the rate of MAO-mediated oxidative deamination; the combination of COMT resistance plus MAO resistance produces meaningful oral bioavailability and a half-life of 3-6 hours (versus 1-2 minutes for catecholamines). Ephedra alkaloids in dietary supplements were associated with cardiovascular events (MI, stroke, sudden death) at the doses used, leading to the 2004 FDA ban.

• Option A: Option A is incorrect: ephedrine is not a pure direct-acting alpha-1 and beta-1 agonist; it has both direct adrenergic receptor agonism and indirect NE-releasing properties — this mixed mechanism (direct + indirect) is what distinguishes ephedrine from phenylephrine (pure direct) and amphetamine (predominantly indirect); the direct component accounts for ephedrine's activity in patients with depleted NE stores (e.g., after reserpine), while the indirect component produces tachyphylaxis with repeated dosing.
• Option B: Option B is the most pharmacologically complete and accurate answer. The marked answer E is incorrect.
• Option C: Option C is incorrect: ephedrine is not a pure indirect sympathomimetic with no direct receptor activity; this confuses ephedrine with pure indirect sympathomimetics like tyramine; ephedrine's direct adrenergic receptor agonism (especially at beta-2 receptors) contributes meaningfully to its clinical effects, particularly bronchodilation (exploited in the past for asthma), and produces some residual activity even when NE stores are depleted.
• Option D: Option D is incorrect: ephedrine is absorbed orally through the standard intestinal mucosa route, not exclusively through buccal mucosa; oral ephedrine achieves adequate systemic bioavailability because it lacks a catechol ring (not a COMT substrate), is MAO-resistant (alpha-methyl group blocking MAO access), and is not highly charged at intestinal pH; the claim of exclusive buccal absorption is not pharmacologically accurate.

ANSWER: B

Rationale:

Pseudoephedrine is the stereoisomer of ephedrine (erythro versus threo configuration) with a predominantly indirect sympathomimetic mechanism and important regulatory and adverse effect considerations. Mechanism: pseudoephedrine is structurally similar to ephedrine but with the hydroxyl and amino groups in the erythro rather than threo spatial arrangement; this stereochemistry confers predominantly indirect sympathomimetic activity (NE release from presynaptic terminals via NET reverse efflux) with a modest direct alpha-1 and alpha-2 agonist component; the indirect NE release activates alpha-1 receptors on nasal submucosal arterioles and venous sinusoids (the erectile tissue of the nasal turbinates), producing vasoconstriction that reduces mucosal blood volume and relieves congestion. Regulatory status: pseudoephedrine is a Schedule-V (List I) chemical regulated under the Combat Methamphetamine Epidemic Act of 2005; it must be kept behind the pharmacy counter (not on open shelves despite OTC status); purchasers must show government-issued photo ID; daily purchase limits (3.6 g) and monthly purchase limits (9 g) are enforced; sales are logged in a national database to detect and prevent large-quantity purchases for illicit manufacturing; pseudoephedrine is the primary chemical precursor for the illicit P2P and pseudoephedrine-reduction methods of methamphetamine synthesis. Adverse effects in elderly males: alpha-1 receptor-mediated contraction of smooth muscle in the internal urethral sphincter and prostatic urethra is the mechanism of urinary retention; in elderly males with benign prostatic hyperplasia (BPH), the prostate gland already narrows the urethral lumen; even a modest pharmacological increase in urethral tone from pseudoephedrine's alpha-1 component can push a patient with BPH from marginal voiding to acute urinary retention; this interaction is particularly dangerous because the patient may not associate the OTC decongestant with the urological emergency; other relevant adverse effects include hypertension (alpha-1-mediated), tachycardia (beta-1 spillover at higher doses), insomnia (CNS stimulation from limited BBB penetration), and anxiety; MAOI co-administration is absolutely contraindicated (hypertensive crisis).

• Option A: Option A is incorrect: pseudoephedrine does not produce nasal decongestion through direct alpha-2 receptor agonism; it is an indirect sympathomimetic that releases NE from sympathetic nerve terminals in the nasal mucosa, and the released NE acts on alpha-1 receptors (not alpha-2) on submucosal blood vessels to produce vasoconstriction and decongestion; alpha-2 receptor agonism in nasal mucosa has been used (oxymetazoline, a direct alpha-2 agonist), but that is not pseudoephedrine's mechanism.
• Option C: Option C is incorrect: pseudoephedrine is not freely available without restriction in all countries; it is specifically regulated in the US under the Combat Methamphetamine Epidemic Act due to its use as a precursor in illicit methamphetamine synthesis; pharmacies track pseudoephedrine purchases and limit quantity per transaction; the characterization of "freely available without restriction" contradicts the regulatory status of pseudoephedrine in the US and many other jurisdictions.
• Option D: Option D is incorrect: pseudoephedrine does not produce nasal decongestion through beta-2 receptor activation; beta-2 activation in nasal submucosal vasculature would produce vasodilation (increasing blood flow and congestion), not vasoconstriction and decongestion; pseudoephedrine's mechanism is indirect alpha-1-mediated vasoconstriction via NE release — the same vasoconstrictor mechanism as direct alpha-1 agonists like phenylephrine, just achieved indirectly.

ANSWER: D

Rationale:

Cocaine-associated myocardial infarction in patients with angiographically normal coronary arteries is a well-documented clinical phenomenon that occurs through the convergence of four independent but synergistic mechanisms. Mechanism 1 -- Alpha-1-mediated coronary vasospasm: cocaine blocks NET, causing NE to accumulate at sympathetic synapses throughout the body including in the coronary adventitia (coronary arteries have sympathetic innervation that primarily mediates alpha-1 vasoconstriction -- unlike skeletal muscle vessels where beta-2 vasodilation can offset alpha-1); accumulated NE activates alpha-1 receptors (Gq-IP3-Ca2+-MLCK) on coronary smooth muscle, producing vasospasm that can completely occlude the vessel; cocaine also directly activates alpha-1 receptors as a sympathomimetic; vasospasm is the primary mechanism of MI in users with normal epicardial coronary arteries. Mechanism 2 -- Beta-1-mediated increased O2 demand: NE accumulation also activates beta-1 receptors, increasing heart rate (reduced diastolic filling time) and contractility (increased O2 per beat); the rate-pressure product rises dramatically; myocardial O2 demand increases precisely as supply is reduced by vasospasm -- a double-edged supply-demand crisis. Mechanism 3 -- Platelet alpha-2 activation and thrombosis: cocaine activates alpha-2 receptors on platelets (Gi-coupled, paradoxically increasing platelet activation signaling through alternative pathways); platelet aggregation at vasospasm sites generates thrombus; the combination of vasospasm (reducing flow and causing endothelial stress) plus platelet activation (generating thrombus) produces coronary thrombosis in arteries that were angiographically normal before cocaine use. Mechanism 4 -- Sodium channel blockade and arrhythmia: cocaine's Nav1 channel blocking effect (the local anesthetic mechanism) applies to cardiac Nav1.5 channels; this slows conduction velocity (widened QRS, prolonged PR on ECG), increases arrhythmia risk from re-entrant circuits, and can precipitate ventricular tachycardia or fibrillation in the ischemic heart; sodium bicarbonate can reverse cocaine conduction toxicity by alkalinizing the sodium channel binding site (the local anesthetic binding site has higher affinity for the ionized form of cocaine, and alkalinization shifts cocaine toward the non-ionized form with lower channel affinity). Management: nitroglycerin (coronary vasodilation, reducing vasospasm); phentolamine (alpha-1 block, directly reversing the vasospasm driver); aspirin and antiplatelet therapy; benzodiazepines (reducing CNS-mediated sympathetic drive); avoiding non-selective beta-blockers (unopposed alpha-1 vasoconstriction).

• Option A: Option A is incorrect: cocaine-associated MI in patients with normal coronary arteries is not caused by Na+ channel blockade on coronary smooth muscle; cocaine's local anesthetic mechanism (Nav1 blockade) in cardiac tissue does cause QRS widening and arrhythmia risk, but coronary vasoconstriction is mediated through alpha-1 adrenergic receptor activation by accumulated NE (from NET blockade), not through local anesthetic sodium channel effects on smooth muscle.
• Option B: Option B is incorrect: cocaine does cause coronary vasoconstriction and thrombosis in patients without pre-existing CAD; cocaine-induced coronary vasospasm occurs via alpha-1-mediated smooth muscle contraction in the coronary arteries (enhanced by NET blockade increasing local NE), and cocaine-enhanced platelet aggregation and thrombosis can cause MI even with angiographically normal coronary arteries; limiting cocaine cardiac toxicity to patients with pre-existing CAD is factually incorrect.
• Option C: Option C is incorrect: cocaine's cardiac toxicity is not primarily mediated by serotonin receptor effects from SERT blockade; cocaine does block SERT and increases synaptic serotonin, but the cardiac consequences of this (5-HT2A-mediated platelet aggregation and some vasoconstriction) are secondary contributions; the dominant mechanisms of cocaine-associated MI are alpha-1-mediated coronary vasospasm (from NET-enhanced NE), direct Na+ channel cardiac toxicity, and enhanced platelet aggregation — not serotonergic coronary microvascular injury.
• Option E: Option E is incorrect: cocaine's cardiovascular toxicity is not mediated solely by DAT blockade and cardiac D1 receptor activation; cardiac sympathetic terminals express very low levels of dopamine D1 receptors; the cardiovascular toxicity of cocaine is primarily from NET/DAT blockade increasing synaptic NE and dopamine at adrenergic (not dopaminergic) cardiac receptors, combined with the sodium channel effects; dopamine accumulation at cardiac D1 receptors is not a major mechanism of cocaine cardiac toxicity.

ANSWER: A

Rationale:

The contraindication of non-selective beta-blockers in cocaine toxicity is one of the most important clinical pharmacology principles in emergency medicine and cardiology. The mechanism -- unopposed alpha stimulation: cocaine blocks NET, accumulating NE in sympathetic synapses throughout the body; the accumulated NE activates: alpha-1 receptors (Gq-IP3-Ca2+-MLCK: vasoconstriction of coronary arteries, peripheral arterioles, and veins -- raising SVR and causing coronary vasospasm) and simultaneously beta-2 receptors (Gs-cAMP-MLCK inhibition: vasodilation in skeletal muscle, splanchnic, and other vascular beds); the net vascular effect of cocaine is a balance between alpha-1 vasoconstriction and beta-2 vasodilation, with a net result that is less vasoconstrictive than pure alpha-1 stimulation would produce; when propranolol (non-selective beta-1 and beta-2 blocker) is administered, it removes the beta-2 vasodilation component entirely while having no effect on the alpha-1 vasoconstriction; the new net vascular effect is the alpha-1 vasoconstriction alone, unopposed and amplified -- coronary vasospasm worsens, SVR rises, and hypertension and ischemia may worsen paradoxically despite administration of a "blood pressure lowering" drug; clinically, cases of cocaine-associated MI following propranolol administration have been reported. Preferred management of cocaine-associated tachycardia: IV benzodiazepines (lorazepam or diazepam): first-line for agitation, anxiety, and tachycardia; reduce cortical and limbic sympathetic drive; lower catecholamine levels; reduce tachycardia and often lower BP without peripheral adrenergic receptor effects. Nitroglycerin: for chest pain and coronary vasospasm. Phentolamine: for severe hypertension (direct alpha-1/alpha-2 block). Labetalol controversy: labetalol combines alpha-1 blockade with beta-1/beta-2 blockade; the alpha-1 component partially prevents unopposed alpha stimulation; it has been used in cocaine toxicity and case series suggest it may be safer than propranolol; however, some guidelines still recommend avoiding all beta-blockers including labetalol in cocaine toxicity due to the persistence of some degree of alpha-1 vasoconstriction unopposed by the retained beta-2 vasodilation.

• Option B: Option B is incorrect: non-selective beta-blockers are not contraindicated in cocaine toxicity because they block DAT; propranolol has no significant DAT-inhibiting activity; non-selective beta-blockers are contraindicated in cocaine toxicity because they block beta-2 receptors, which are the main mediators of compensatory vasodilation in peripheral vasculature; removing beta-2 vasodilation while leaving alpha-1 vasoconstriction unopposed from the cocaine-induced NE surge produces dangerous hypertension and coronary vasospasm.
• Option C: Option C is definitively incorrect -- the beta-blocker contraindication in cocaine toxicity is supported by mechanistic evidence, case reports, and is reflected in ACC/AHA and toxicology guidelines.
• Option D: Option D is incorrect: non-selective beta-blockers are not selectively contraindicated only in cocaine-associated MI but safe for cocaine tachycardia without MI; the mechanism of the contraindication (unopposed alpha-1 vasoconstriction from beta-2 blockade) applies whenever cocaine is on board producing adrenergic excess, regardless of whether MI has occurred; tachycardia management in cocaine toxicity should use benzodiazepines rather than beta-blockers for this reason.

ANSWER: C

Rationale:

Lisdexamfetamine's prodrug design is a pharmacological innovation in reducing abuse potential, though the reduction is partial rather than complete. Prodrug structure: lisdexamfetamine dimesylate consists of dextroamphetamine covalently conjugated to the natural amino acid L-lysine via an amide bond at dextroamphetamine's primary amine group; the intact lisdexamfetamine molecule is pharmacologically inactive -- it has no meaningful affinity for NET, DAT, or any adrenergic receptor in its unconverted form; it is absorbed orally via peptide/amino acid transporters in the small intestine (because the lysine moiety is recognized as a dipeptide). Enzymatic activation: after absorption, lisdexamfetamine is converted to dextroamphetamine primarily by peptidase enzymes in erythrocytes (red blood cell peptidases, including tripeptidyl peptidase II and others); this enzymatic cleavage is the rate-limiting step for dextroamphetamine generation; because the conversion is enzyme-limited (not absorption-rate-limited), peak dextroamphetamine concentrations rise more slowly and reach a lower Cmax than after equivalent oral immediate-release dextroamphetamine. Abuse deterrence mechanism: the reinforcing (euphoric) properties of amphetamines depend on a rapid, sharp rise in dopamine in the nucleus accumbens (mesolimbic reward circuit); a slower Cmax rise produces less intense dopamine spike and less euphoric reinforcement; intranasal or IV administration of lisdexamfetamine is partially blocked as an abuse route because the lysine-amphetamine conjugate must still be enzymatically cleaved by blood-borne peptidases -- crushing and snorting lisdexamfetamine does not produce the same rapid dextroamphetamine delivery as crushing and snorting dextroamphetamine directly; studies confirm significantly lower subjective "drug liking" ratings for intranasal lisdexamfetamine versus intranasal d-amphetamine. Remaining abuse potential: dextroamphetamine is fully generated regardless of route, given sufficient time; oral lisdexamfetamine at supratherapeutic doses can produce significant euphoria; lisdexamfetamine remains Schedule II -- its abuse potential is reduced, not eliminated.

• Option A: Option A is incorrect: lisdexamfetamine does not reduce abuse potential through a polymer matrix physical barrier; it is a prodrug design — lisdexamfetamine is dextroamphetamine covalently bonded to L-lysine; after oral absorption, enzymatic cleavage by plasma peptidases is required to release active dextroamphetamine; intranasal or IV administration of crushed lisdexamfetamine produces less euphoria because the systemic enzymatic conversion rate limits the speed of dextroamphetamine release, preventing the sharp peak plasma concentration required for euphoria.
• Option B: Option B provides the most complete and pharmacologically accurate account of both the mechanism and its limitations.
• Option D: Option D is incorrect: lisdexamfetamine does not eliminate all abuse potential; it remains Schedule II under the DEA; the prodrug design reduces abuse potential by slowing the rate of dextroamphetamine release even with alternative routes of administration, but at sufficiently high doses or in determined individuals, euphoria is still achievable; the FDA and DEA classification as Schedule II (not Schedule IV as stated) confirms that abuse potential is reduced but not eliminated.